About the Isoflavone Drug Technology:
Metavone has intellectual property rights to two patent families covering its Isoflavone Drug Technology (IDT). Isoflavones are naturally occurring compounds found in plants, most commonly in soy. They are essentially antioxidants with multiple functions, and they have a similar structure to the hormone estrogen. Interest in isoflavones was initially sparked by the observation that countries where soy consumption is high tend to have low rates of hormone-related cancers (such as breast, prostate and ovarian cancer), menopausal problems, osteoporosis and dementia.
This Technology features a suite of 138 isoflavone compounds that the Company will seek to develop as therapeutic treatments for dementia and hormone-related cancers.
The Company has not committed to any royalties or encumbrances in respect of the Isoflavone Drug Technology. The Company has full commercial discretion to commercialise the IP in any way it so chooses. This includes the use of the compounds developed from the Isoflavone Drug Technology for the treatment of a range of diseases and syndromes including dementia, hormone-related cancers, osteoporosis, menopausal symptoms, diabetes and coronary heart disease. Currently, the Company is targeting dementia and hormone-related cancer treatments.